Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration - Concepedia

Concepedia

Publication | Closed Access

Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration

577

Citations

25

References

2014

Year

Allen C. Ho, Brandon Busbee, Carl D. Regillo, Mark R. Wieland, Sherri A. Van Everen, Zhengrong Li, Roman G. Rubio, Phillip Lai

References

	Year	Citations

Page 1